Citius Pharmaceuticals (CTXR) Q4 2025 earnings summary

Executive summary

• Launched LYMPHIR, a novel immunotherapy for relapsed/refractory Stage I-III CTCL, in the U.S. in December 2025 following FDA approval.

• Focused on commercial launch, expanding market access, and advancing pipeline assets Mino-Lok and Halo-Lido.

• Secured distribution agreements, ensured 18 months of LYMPHIR supply, and achieved NCCN guideline inclusion.

Financial highlights

• Cash and cash equivalents stood at $4.3 million as of September 30, 2025.

• No revenues reported for fiscal year 2025.

• R&D expenses were $9.2 million, down from $11.9 million year-over-year.

• G&A expenses were $18.5 million, slightly up from $18.2 million year-over-year.

• Net loss was $39.7 million, or ($3.38) per share, compared to $40.2 million, or ($5.97) per share, in the prior year.

Outlook and guidance

• Management expects significant growth opportunities with LYMPHIR's U.S. launch and international expansion.

• Ongoing engagement with the FDA for Mino-Lok and Halo-Lido to advance late-stage pipeline.